Table 3.
Individual AAOS guidelines AGREE II domain scores organized in ascending order of average AGREE II score.
AAOS Guideline Title | Scope and Purpose |
Stakeholder Involvement |
Rigor of Development |
Clarity of Presentation |
Applicability |
Editorial Independence |
Average AGREE II |
---|---|---|---|---|---|---|---|
Avg. AGREE II Score ±95% CI (Avg. %) | Avg. AGREE II Score ±95% CI (Avg. %) | Avg. AGREE II Score ±95% CI (Avg. %) | Avg. AGREE II Score ±95% CI (Avg. %) | Avg. AGREE II Score ±95% CI (Avg. %) | Avg. AGREE II Score ±95% CI (Avg. %) | Avg. AGREE II Score ±95% CI (Avg. %) | |
Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures | 5.30 ± 0.91 (82) | 5.32 ± 1.24 (83) | 5.31 ± 1.22 (84) | 5.35 ± 1.12 (85) | 2.32 ± 0.47 (41) | 5.34 ± 1.10 (85) | 5.36 ± 1.11 (85) |
Acute Compartment Syndrome | 5.15 ± 1.25 (80) | 5.19 ± 0.93 (81) | 5.20 ± 0.96 (82) | 5.22 ± 0.97 (83) | 2.48 ± 0.39 (45) | 5.21 ± 0.98 (82) | 5.20 ± 0.99 (82) |
Management of Osteoarthritis of the Knee (Non-Arthroplasty) | 5.89 ± 1.08 (95) | 5.88 ± 1.03 (94) | 5.86 ± 1.11 (93) | 5.87 ± 1.09 (94) | 2.94 ± 0.34 (54) | 5.85 ± 1.05 (94) | 5.84 ± 1.04 (93) |
Use of Imaging Prior to Referral to a Musculoskeletal Oncologist | 5.26 ± 1.21 (84) | 5.23 ± 1.29 (82) | 5.24 ± 1.13 (83) | 5.27 ± 1.15 (84) | 2.51 ± 0.45 (46) | 5.28 ± 1.14 (84) | 5.29 ± 1.13 (84) |
Treatment of Pediatric Supracondylar Humerus Fractures | 5.17 ± 0.88 (81) | 5.18 ± 0.85 (81) | 5.17 ± 0.89 (81) | 5.18 ± 0.83 (81) | 2.17 ± 0.38 (40) | 5.19 ± 0.81 (82) | 5.16 ± 0.82 (80) |
Treatment of Metastatic Carcinoma and Myeloma of the Femur | 5.21 ± 1.14 (83) | 5.25 ± 1.02 (83) | 5.28 ± 1.01 (84) | 5.30 ± 1.03 (84) | 2.41 ± 0.37 (43) | 5.29 ± 1.02 (84) | 5.28 ± 1.00 (83) |
Clinical Practice Guideline for the Treatment of Clavicle Fractures | 5.41 ± 0.97 (85) | 5.42 ± 1.11 (85) | 5.46 ± 1.15 (86) | 5.44 ± 1.11 (86) | 2.58 ± 0.35 (49) | 5.45 ± 1.13 (86) | 5.43 ± 1.14 (86) |
Evaluation of Psychosocial Factors Influencing Recovery from Adult Orthopaedic Trauma | 5.48 ± 1.09 (86) | 5.47 ± 0.92 (86) | 5.50 ± 0.94 (87) | 5.49 ± 0.90 (87) | 2.89 ± 0.33 (53) | 5.48 ± 0.89 (87) | 5.47 ± 0.87 (87) |
Diagnosis and Treatment of Osteochondritis Dissecans | 5.33 ± 0.94 (84) | 5.34 ± 1.05 (85) | 5.36 ± 1.06 (85) | 5.38 ± 1.07 (86) | 2.52 ± 0.36 (46) | 5.37 ± 1.08 (85) | 5.38 ± 1.09 (86) |
Pharmacologic, Physical, and Cognitive Pain Alleviation for Musculoskeletal Extremity/Pelvis Surgery | 5.22 ± 1.11 (83) | 5.21 ± 0.97 (82) | 5.23 ± 1.04 (83) | 5.26 ± 1.06 (84) | 2.46 ± 0.40 (44) | 5.24 ± 1.04 (83) | 5.25 ± 1.03 (83) |
Diagnosis and Prevention of Periprosthetic Joint Infections | 5.64 ± 0.96 (89) | 5.62 ± 1.19 (89) | 5.61 ± 1.12 (88) | 5.63 ± 1.10 (88) | 2.72 ± 0.31 (51) | 5.62 ± 1.11 (88) | 5.60 ± 1.12 (88) |
Management of Distal Radius Fractures | 5.28 ± 1.00 (84) | 5.27 ± 0.90 (83) | 5.29 ± 0.92 (84) | 5.32 ± 0.94 (85) | 2.35 ± 0.38 (42) | 5.31 ± 0.95 (84) | 5.33 ± 0.96 (85) |
Treatment of Pediatric Diaphyseal Femur Fractures | 5.50 ± 1.19 (87) | 5.51 ± 1.13 (87) | 5.53 ± 1.19 (88) | 5.55 ± 1.18 (88) | 2.67 ± 0.34 (50) | 5.54 ± 1.15 (88) | 5.53 ± 1.16 (88) |
Management of Surgical Site Infections | 5.53 ± 0.95 (88) | 5.54 ± 0.99 (88) | 5.52 ± 0.98 (88) | 5.53 ± 0.89 (88) | 2.62 ± 0.33 (49) | 5.52 ± 0.87 (87) | 5.50 ± 0.86 (87) |
Management of Osteoarthritis of the Hip (update pending) | 5.40 ± 1.02 (85) | 5.37 ± 1.20 (85) | 5.40 ± 1.16 (85) | 5.42 ± 1.14 (86) | 2.53 ± 0.39 (47) | 5.41 ± 1.16 (86) | 5.40 ± 1.15 (85) |
Management of Glenohumeral Joint Osteoarthritis | 5.11 ± 1.31 (80) | 5.12 ± 1.28 (80) | 5.13 ± 1.26 (80) | 5.14 ± 1.24 (80) | 2.19 ± 0.37 (40) | 5.15 ± 1.22 (81) | 5.13 ± 1.20 (80) |
Limb Salvage or Early Amputation | 5.70 ± 0.86 (91) | 5.69 ± 0.88 (91) | 5.71 ± 0.90 (92) | 5.72 ± 0.88 (92) | 2.92 ± 0.32 (53) | 5.73 ± 0.84 (92) | 5.74 ± 0.83 (92) |
Carpal Tunnel Syndrome (update pending) | 5.56 ± 1.05 (89) | 5.57 ± 1.04 (88) | 5.56 ± 1.06 (88) | 5.59 ± 1.07 (89) | 2.64 ± 0.34 (49) | 5.58 ± 1.08 (89) | 5.57 ± 1.09 (89) |
Venous Thromboembolic Disease in Elective TKA and THA | 5.60 ± 1.22 (90) | 5.59 ± 1.10 (89) | 5.58 ± 1.14 (89) | 5.57 ± 1.12 (89) | 2.56 ± 0.36 (48) | 5.56 ± 1.13 (89) | 5.55 ± 1.10 (88) |
Detection and Nonoperative Management of Pediatric Developmental Dysplasia of the Hip in Infants Up to 6 Months of Age | 5.08 ± 1.17 (79) | 5.09 ± 1.15 (79) | 5.10 ± 1.18 (80) | 5.11 ± 1.16 (80) | 2.16 ± 0.35 (39) | 5.12 ± 1.17 (81) | 5.14 ± 1.18 (80) |
Management of Anterior Cruciate Ligament Injuries | 5.75 ± 1.16 (92) | 5.76 ± 1.07 (92) | 5.77 ± 1.09 (93) | 5.78 ± 1.05 (93) | 2.87 ± 0.30 (52) | 5.79 ± 1.03 (93) | 5.80 ± 1.02 (93) |
Management of Rotator Cuff Injuries | 5.16 ± 1.03 (81) | 5.17 ± 0.95 (81) | 5.18 ± 0.91 (81) | 5.19 ± 0.92 (82) | 2.24 ± 0.39 (41) | 5.20 ± 0.90 (82) | 5.19 ± 0.88 (82) |
Surgical Management of Osteoarthritis of the Knee | 5.35 ± 0.99 (84) | 5.36 ± 1.01 (84) | 5.38 ± 1.03 (86) | 5.37 ± 1.01 (85) | 2.44 ± 0.37 (44) | 5.39 ± 0.99 (86) | 5.39 ± 0.98 (85) |
Prevention of Surgical Site Infection After Major Extremity Trauma | 5.20 ± 1.26 (82) | 5.22 ± 1.16 (82) | 5.21 ± 1.10 (82) | 5.23 ± 1.08 (83) | 2.50 ± 0.38 (45) | 5.22 ± 1.09 (83) | 5.23 ± 1.07 (82) |
Anesthesia and Analgesia in Total Joint Arthroplasty (2021) | 5.13 ± 1.15 (80) | 5.14 ± 1.12 (80) | 5.15 ± 1.20 (80) | 5.16 ± 1.18 (81) | 2.27 ± 0.36 (42) | 5.17 ± 1.19 (82) | 5.18 ± 1.17 (81) |
Tranexamic Acid in Total Joint Arthroplasty | 5.19 ± 1.30 (82) | 5.20 ± 1.14 (82) | 5.19 ± 1.05 (81) | 5.21 ± 1.04 (82) | 2.42 ± 0.35 (43) | 5.23 ± 1.06 (83) | 5.24 ± 1.05 (83) |
Anesthesia and Analgesia in Total Joint Arthroplasty (2020) | 5.67 ± 0.89 (90) | 5.65 ± 0.91 (90) | 5.66 ± 0.87 (90) | 5.68 ± 0.86 (91) | 2.76 ± 0.31 (51) | 5.67 ± 0.85 (90) | 5.66 ± 0.84 (90) |
Management of Hip Fractures in Older Adults | 5.58 ± 1.11 (89) | 5.55 ± 1.08 (88) | 5.54 ± 1.02 (87) | 5.56 ± 1.00 (88) | 2.60 ± 0.33 (48) | 5.55 ± 1.01 (87) | 5.54 ± 0.99 (88) |
AAOS = American Academy of Orthopaedic Surgeons ⎟ TKA = Total Knee Arthroplasty ⎟ THA = Total Hip Arthroplasty.